What is GRAL stock price today?

GRAL (GRAIL, LLC) stock is trading at $101.31 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is GRAL stock going up or down today?

GRAL stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy GRAL stock now?

The decision to buy GRAL depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is GRAL a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for GRAL based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is GRAL stock overvalued or undervalued?

Use our DCF valuation calculator to determine if GRAL is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is GRAL's P/E ratio?

P/E ratio data for GRAL will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is GRAL's market cap?

GRAL (GRAIL, LLC) has a market capitalization of $3.95 billion, making it a small-cap stock.

What is GRAL's price to book ratio?

GRAL trades at a price-to-book (P/B) ratio of 1.76, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does GRAL pay dividends?

GRAL does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is GRAL's dividend yield?

GRAL does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is GRAL stock a good long-term investment?

GRAL's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is GRAL's revenue growth rate?

GRAL has shown revenue growth of 0.3% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

GRAL is currently operating at a loss. Some companies prioritize growth over profitability in early stages. Review our financial analysis for detailed insights.

What are the risks of investing in GRAL?

Key risks for GRAL include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does GRAL compare to its competitors?

Compare GRAL to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize GRAL's performance and positioning.

What is GRAL's stock price target for 2026?

Our AI model provides price targets for GRAL based on fundamental analysis: Bull case $131.70 (+30%), Base case $116.51 (+15%), Bear case $91.18 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about GRAL?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for GRAL. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is GRAL's next earnings report?

GRAL reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

GRAL - GRAIL, LLC

NYSE * Healthcare * Diagnostics & Research

$101.31

+$4.61 (+4.77%)

About GRAIL, LLC

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, it develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California.

GRAL Key Statistics

Market Cap

$3.95B

P/B Ratio

1.76

EPS

$-10.66

Revenue Growth

+0.3%

Profit Margin

-2.9%

Employees

1,000

How GRAL Compares to Peers

GRAL ranks 2nd in revenue growth vs peers

GRAL is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
GRAL(This stock)	$3.95B	N/A	0%	-2.9%	-
UNHUnitedhealth Group	$306.56B	17.6	0%	0.0%	vs UNH
JNJJohnson &	$525.73B	21.1	0%	0.3%	vs JNJ
LLYEli Lilly	$933.47B	51.0	1%	0.3%	vs LLY
PFEPfizer Inc	$145.10B	14.8	-0%	0.2%	vs PFE
ABBVAbbvie Inc	$378.29B	160.9	0%	0.0%	vs ABBV

GRAIL, LLC Company Information

Headquarters: 1525 O?Brien Drive, Menlo Park, CA, United States, 94025, undefined
Website: grail.com
Sector: Healthcare
Industry: Diagnostics & Research

GRAL - GRAIL, LLC

About GRAIL, LLC

GRAL Key Statistics

How GRAL Compares to Peers

GRAIL, LLC Company Information

GRAL Lician Score

GRAL Financial Snowflake

Upcoming Events for GRAL